Q1 2024 EPS Estimates for Editas Medicine, Inc. Boosted by Analyst (NASDAQ:EDIT) : vimarsana.com

Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Zacks Research increased their Q1 2024 EPS estimates for shares of Editas Medicine in a research note issued on Thursday, February 15th. Zacks Research analyst A. Chakraborty now expects that the company will earn ($0.71) per share for the quarter, up from their prior estimate […]

Related Keywords

, Russell Investments Group Ltd , Editas Medicine Inc , Nasdaq , Editas Medicine Company Profile , Covestor Ltd , Lazard Asset Management , Citigroup , Zacks Research , Analysts At Zacks Research , Editas Medicine , Free Report , Asset Management , Investments Group , Clear Street Markets , Get Free Report , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Edit , Medical , Earnings Estimates ,